1.54
0.02 (1.32%)
| Penutupan Terdahulu | 1.52 |
| Buka | 1.51 |
| Jumlah Dagangan | 51,979 |
| Purata Dagangan (3B) | 196,373 |
| Modal Pasaran | 9,475,558 |
| Harga / Pendapatan (P/E Ke hadapan) | 2.97 |
| Harga / Jualan (P/S) | 12.22 |
| Harga / Buku (P/B) | 3.79 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 27 Mar 2025 - 31 Mar 2025 |
| Margin Operasi (TTM) | -1,295.57% |
| EPS Cair (TTM) | -2.60 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -19.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.30% |
| Nisbah Semasa (MRQ) | 2.93 |
| Aliran Tunai Operasi (OCF TTM) | -7.43 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -4.55 M |
| Pulangan Atas Aset (ROA TTM) | -57.46% |
| Pulangan Atas Ekuiti (ROE TTM) | -157.62% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Can-Fite Biopharma Ltd Sponsore | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.13 |
|
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Institusi | 1.49% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Kohmann Bosshard Financial Services, Llc | 31 Dec 2024 | 3,401 |
| Fifth Third Bancorp | 31 Dec 2024 | 3,000 |
| Activest Wealth Management | 31 Dec 2024 | 200 |
| Td Waterhouse Canada Inc. | 31 Dec 2024 | 20 |
| Avion Wealth | 31 Dec 2024 | 0 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 12 Nov 2013 | - | 25 Nov 2013 | 0.169622 Tunai |
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2013 | 0.170 | 1 | 0.02 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |